Navigate
X
    QualityStocks
  • 17 years ago

Delcath Systems, Inc. (NASDAQ: DCTH)

Delcath Systems, Inc. (NASDAQ: DCTH), a medical technology company specializing in cancer treatment, is currently testing a proprietary, patented drug delivery system designed to treat liver cancers. The company is enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. Twenty-eight international patents consist of the Company’s intellectual property portfolio. For further information, visit the Company’s web site at www.delcath.com.

Tags Rodman & Renshaw
Related Post
  1. QualityStocksNewsBreaks – Powering AI: Nicola Mining Inc.’s (TSX.V: NIM) (OTCQB: HUSIF) Copper Project Aligns with Data Center Surge

    As artificial intelligence (“AI”) continues to revolutionize industries, the infrastructure supporting its growth has become…

  2. Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Breaks Ground on REE Processing Facility, Pioneers Domestic Supply Chain

    The company announced the groundbreaking of its Louisiana Strategic Metals Complex (“SMC”) in Alexandria. The…

  3. NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

    The new FDA voucher program aims to speed approval of drugs aligned with national health…